Saturday, August 23, 2025 8/23/2025

Myobacterium tuberculosis Phenylalanine Synthesis as a Novel Drug Target

Award Number: R21AI193559
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2025
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

Myobacterium tuberculosis Phenylalanine Synthesis as a Novel Drug Target - PROJECT SUMMARY / ABSTRACT Metabolic pathways that Mycobacterium tuberculosis (Mtb) requires for growth in lab culture conditions and that are highly vulnerable to inhibition have been proposed as novel drug targets. Amino acid biosynthetic pathways represent promising drug targets because they are essential for Mtb growth but are absent in humans. However, we do not yet know which of these pathways Mtb requires during infection or how their inhibition influences susceptibility to existing antibiotics. The overall objective of this exploratory proposal is to determine the potential of phenylalanine (Phe) biosynthesis as a novel anti-tubercular drug target. The central hypothesis is that inhibition of Mtb Phe synthesis disrupts multiple central metabolic pathways to cause death of Mtb and enhance susceptibility to existing antibiotics. Preliminary data show that Mtb starved for Phe die in vitro and that a Phe auxotroph is rapidly cleared from acutely infected mice. Aim 1 will develop Mtb strains that conditionally express enzymes in the Phe biosynthesis pathway. These strains will be used in macrophage and mouse infection models to determine the extent to which Mtb requires Phe synthesis during infection and how Phe synthesis inhibition influences efficacy of existing anti-tubercular drugs. Aim 2 will use transcriptomic and metabolomic analyses of Phe-starved Mtb to identify the metabolic changes and stress responses induced upon inhibition of Phe synthesis. The proposed research is expected to be significant because it will establish Phe synthesis as a promising target for development of new drugs to treat tuberculosis and enable future high- throughput screens to identify small molecules that inhibit Phe synthesis.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $423,500 )
2025	2025	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Allergy and Infectious Diseases Research	000	1	7/1/2025	NEW	$423,500
														Subtotal = $423,500

Grand Total All Awards = $423,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Myobacterium tuberculosis Phenylalanine Synthesis as a Novel Drug Target

Award Number: R21AI193559

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2025

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer